United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant’s Trademark Application
| U.S. Application Serial No. 79329104 Mark: IGE | |
| Correspondence Address: | |
| Applicant: NOVARTIS AG | |
| Reference/Docket No. N/A Correspondence Email Address: | |
NONFINAL OFFICE ACTION
International Registration No. 1634445
Notice of Provisional Full Refusal
Deadline for responding. The USPTO must receive applicant’s response within six months of the “date on which the notification was sent to WIPO (mailing date)” located on the WIPO cover letter, or the U.S. application will be abandoned (see https://www.uspto.gov/trademarks-application-process/abandoned-applications for information on abandonment). To confirm the mailing date, go to the USPTO’s Trademark Status and Document Retrieval (TSDR) database at https://tsdr.uspto.gov/, select “US Serial, Registration, or Reference No.,” enter the U.S. application serial number in the blank text box, and click on “Documents.” The mailing date used to calculate the response deadline is the “Create/Mail Date” of the “IB-1rst Refusal Note.”
Respond to this Office action using the USPTO’s Trademark Electronic Application System (TEAS). A link to the appropriate TEAS response form appears at the end of this Office action.
Discussion of provisional full refusal. This is a provisional full refusal of the request for extension of protection to the United States of the international registration, known in the United States as a U.S. application based on Trademark Act Section 66(a). See 15 U.S.C. §§1141f(a), 1141h(c).
The lettering "IGE" is defined as "immunoglobulin E." See https://www.ahdictionary.com/word/search.html?q=IgE. Other entities use this abbreviation to describe similar goods and services. See, e.g., https://www.cerascreen.com/products/extensive-food-sensitivity-test ("Our lab tests the concentration of IgE and IgG4 antibodies in your blood,"); https://www.gdx.net/product/ige-food-allergy-test-blood ("Conditions associated with IgE food allergy"); https://www.nationaljewish.org/conditions/medications/asthma-medications/longterm/faqs-anti-ige-treatment ("Xolair is made to be similar to natural antibodies and is designed specifically to capture most of the IgE and block the allergic response."). This evidence supports that applicant's pharmaceuticals and health information is used in connection or for specific immunoglobulin E antibodies.
Applicant may respond to this issue by submitting a disclaimer in the following format:
No claim is made to the exclusive right to use “IGE” apart from the mark as shown.
For an overview of disclaimers and instructions on how to provide one using the Trademark Electronic Application System (TEAS), see the Disclaimer webpage.
The following description is suggested, if accurate: The mark consists of the lettering "IGE" in blue and white where a blue knife forms the "I", a white fork and spoon, and blue plate form part of the "G" and a blue fork forms the "E". The lettering appears on a white background within a blue circle. Eight solid blue circles appear around the blue circle and eight white and blue circles appear around this with designs within the circles. These designs are of three nuts, a fish with bubbles above, a shrimp, a [indicate design, e.g., a soy bean], a crab, a milk carton with a brain on the side and a bottle of milk, hops, and an [indicate design, e.g., egg] respectively and all in blue and white. These circles appear on a white background and within a blue outlined circle. The background of the mark appears in white.
RESPONSE
The USPTO does not accept emails as responses to Office actions; however, emails can be used for informal communications and are included in the application record. See 37 C.F.R. §§2.62(c), 2.191; TMEP §§304.01-.02, 709.04-.05.
How to respond. Click to file a response to this nonfinal Office action.
/Megan M. Hartnett/
Megan M. Hartnett
Trademark Examining Attorney
Law Office 123
571-270-1977
megan.hartnett@uspto.gov
RESPONSE GUIDANCE